Endocannabinoids in the Gut

Cannabis and Cannabinoid Research

Volumn 1, Issue 1, 2016, Pages 67-77

  Dipatrizio, Nicholas V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cannabinoid receptor type 1; endocannabinoid; enteric nervous system; gut?brain; microbiome; peristalsis; vagus nerve

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID;

CHOLINERGIC TRANSMISSION; DIGESTIVE SYSTEM FUNCTION DISORDER; FAT INTAKE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT FUNCTION; GUT BRAIN SIGNALING; HUMAN; HUNGER; INFLAMMATORY BOWEL DISEASE; INTESTINE; INTESTINE FLORA; INTESTINE INNERVATION; INTESTINE MUCOSA PERMEABILITY; NEUROMODULATION; NONHUMAN; PARASYMPATHETIC FUNCTION; PRIORITY JOURNAL; REVIEW; STOMACH SECRETION; VAGAL PARASYMPATHETIC CONTROL;

EID: 85025151683     PISSN: None     EISSN: 23788763     Source Type: Journal    
DOI: 10.1089/can.2016.0001     Document Type: Review

References (79)

1. Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010;126:21-38.
2. Trautmann SM, Sharkey KA. The endocannabinoid system and its role in regulating the intrinsic neural circuitry of the gastrointestinal tract. Int Rev Neurobiol. 2015;125:85-126.
3. DiPatrizio NV, Piomelli D. The thrifty lipids: endocannabinoids and the neural control of energy conservation. Trends Neurosci. 2012;35:403-411.
4. DiPatrizio NV, Piomelli D. Intestinal lipid-derived signals that sense dietary fat. J Clin Invest. 2015;125:891-898.
5. Izzo AA, Piscitelli F, Capasso R, et al. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol. 2009;158:451-461.
6. Camilleri M, Carlson P, McKinzie S, et al. Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am J Physiol. 2008;294:G13-G19.
7. Camilleri M, Kolar GJ, Vazquez-Roque MI, et al. Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traits. Am J Physiol. 2013;304:G553-G560.
8. Wong BS, Camilleri M, Busciglio I, et al. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology. 2013;141:1638-1647.e1631-e1637.
9. Devane WA, Dysarz FA, 3rd, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34:605-613.
10. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561-564.
11. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990;87:1932-1936.
12. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1949.
13. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50:83-90.
14. Chesher GB, Dahl CJ, Everingham M, et al. The effect of cannabinoids on intestinal motility and their antinociceptive effect in mice. Br J Pharmacol. 1973;49:588-594.
15. Gill EW, Paton WD, Pertwee RG. Preliminary experiments on the chemistry and pharmacology of cannabis. Nature. 1970;228:134-136.
16. Roth SH. Stereospecific presynaptic inhibitory effect of delta9-tetrahydrocannabinol on cholinergic transmission in the myenteric plexus of the guinea pig. Can J Physiol Pharmacol. 1978;56:968-975.
17. Layman JM, Milton AS. Some actions of delta-1 tetrahydrocannabinol and cannabidiol at cholinergic junctions. Br J Pharmacol. 1971;41:379P-380P.
18. Coutts AA, Pertwee RG. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol. 1997;121:1557-1566.
19. Croci T, Manara L, Aureggi G, et al. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol. 1998;125:1393-1395.
20. Izzo AA, Mascolo N, Borrelli F, et al. Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors. Br J Pharmacol. 1998;124:1363-1368.
21. Baldassano S, Serio R, Mule F. Cannabinoid CB(1) receptor activation modulates spontaneous contractile activity in mouse ileal longitudinal muscle. Eur J Pharmacol. 2008;582:132-138.
22. Coutts AA, Brewster N, Ingram T, et al. Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine. Br J Pharmacol. 2008;129:645-652.
23. Coutts AA, Irving AJ, Mackie K, et al. Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol. 2002;448:410-422.
24. Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A. 2002;99:10819-10824.
25. Duncan M, Thomas AD, Cluny NL, et al. Distribution and function of monoacylglycerol lipase in the gastrointestinal tract. Am J Physiol. 2008;295:G1255-G1265.
26. Bashashati M, Nasser Y, Keenan C, et al. Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation. Br J Pharmacol. 2015;172:3099-3111.
27. Jung KM, Astarita G, Zhu C, et al. A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Mol Pharmacol. 2007;72:612-621.
28. Mule F, Amato A, Baldassano S, et al. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations. Pharmacol Res. 2007;56:185-192.
29. Boesmans W, Ameloot K, van den Abbeel V, et al. Cannabinoid receptor 1 signalling dampens activity and mitochondrial transport in networks of enteric neurones. Neurogastroenterol Motil. 2009;21:958-e977.
30. Artmann A, Petersen G, Hellgren LI, et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta. 2008;1781:200-212.
31. Pertwee RG. Endocannabinoids and their pharmacological actions. Handb Exp Pharmacol. 2015;231:1-37.
32. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998;50:413-492.
33. Baldassano S, Zizzo MG, Serio R, et al. Interaction between cannabinoid CB1 receptors and endogenous ATP in the control of spontaneous mechanical activity in mouse ileum. Br J Pharmacol. 2009;158:243-251.
34. Hons IM, Storr MA, Mackie K, et al. Plasticity of mouse enteric synapses mediated through endocannabinoid and purinergic signaling. Neurogastroenterol Motil. 2012;24:e113-e124.
35. Abraham WC, Bear MF. Metaplasticity: the plasticity of synaptic plasticity. Trends Neurosci. 1996;19:126-130.
36. Deisseroth K, Bito H, Schulman H, et al. Synaptic plasticity: a molecular mechanism for metaplasticity. Curr Biol. 1995;5:1334-1338.
37. Berthoud HR. The vagus nerve, food intake and obesity. Regul Pept. 2008;149:15-25.
38. Vianna CR, Donato J, Jr., Rossi J, et al. Cannabinoid receptor 1 in the vagus nerve is dispensable for body weight homeostasis but required for normal gastrointestinal motility. J Neurosci. 2012;32:10331-10337.
39. Krowicki ZK, Moerschbaecher JM, Winsauer PJ, et al. Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. Eur J Pharmacol. 1999;371:187-196.
40. Gomez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci. 2002;22:9612-9617.
41. Cluny NL, Vemuri VK, Chambers AP, et al. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol. 2011;161:629-642.
42. DiPatrizio NV, Astarita G, Schwartz G, et al. Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci U S A. 2011;108:12904-12908.
43. DiPatrizio NV, Igarashi M, Narayanaswami V, et al. Fasting stimulates 2-AG biosynthesis in the small intestine: role of cholinergic pathways. Am J Physiol Regul Integr Comp Physiol. 2015;309:R805-R813.
44. Randall PA, Vemuri VK, Segovia KN, et al. The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol Biochem Behav. 2010;97:179-184.
45. Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest. 2010;120:2953-2966.
46. LoVerme J, Duranti A, Tontini A, et al. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett. 2009;19:639-643.
47. Greenberg D, Smith GP. The controls of fat intake. Psychosom Med. 1996;58:559-569.
48. DiPatrizio NV. Is fat taste ready for primetime? Physiol Behav. 2014;136:145-154.
49. Gilbertson TA, Khan NA. Cell signaling mechanisms of oro-gustatory detection of dietary fat: advances and challenges. Prog Lipid Res. 2013;53:82-92.
50. Mattes RD. Accumulating evidence supports a taste component for free fatty acids in humans. Physiol Behav. 2011;104:624-631.
51. Besnard P, Passilly-Degrace P, Khan NA. Taste of fat: a sixth taste modality? Physiol Rev. 2016;96:151-176.
52. Running CA, Craig BA, Mattes RD. Oleogustus: the unique taste of fat. Chem Senses. 2015;40:507-516.
53. DiPatrizio NV, Joslin A, Jung KM, et al. Endocannabinoid signaling in the gut mediates preference for dietary unsaturated fats. FASEB J. 2013;27:2513-2520.
54. Monteleone P, Piscitelli F, Scognamiglio P, et al. Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: a pilot study. J Clin Endocrinol Metab. 2012;97:E917-E924.
55. Rigamonti AE, Piscitelli F, Aveta T, et al. Anticipatory and consummatory effects of (hedonic) chocolate intake are associated with increased circulating levels of the orexigenic peptide ghrelin and endocannabinoids in obese adults. Food Nutr Res. 2015;59:29678.
56. Mennella I, Ferracane R, Zucco F, et al. Food liking enhances the plasma response of 2-arachidonoylglycerol and of pancreatic polypeptide upon modified sham feeding in humans. J Nutr. 2015;145:2169-2175.
57. Pradhan SN, Roth T. Comparative behavioral effects of several anticholinergic agents in rats. Psychopharmacologia. 1968;12:358-366.
58. Lorenz D, Nardi P, Smith GP. Atropine methyl nitrate inhibits sham feeding in the rat. Pharmacol Biochem Behav. 1978;8:405-407.
59. Sykaras AG, Demenis C, Case RM, et al. Duodenal enteroendocrine I-cells contain mRNA transcripts encoding key endocannabinoid and fatty acid receptors. PLoS One. 2012;7:e42373.
60. Smith GP, Jerome C, Cushin BJ, et al. Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science. 1981;213:1036-1037.
61. Smith GP, Jerome C, Norgren R. Afferent axons in abdominal vagus mediate satiety effect of cholecystokinin in rats. Am J Physiol. 1985;249:R638-R641.
62. Izzo AA, Mascolo N, Borrelli F, et al. Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1999;359:65-70.
63. Izzo AA, Mascolo N, Pinto L, et al. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol. 1999;384:37-42.
64. Tyler K, Hillard CJ, Greenwood-Van Meerveld B. Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. Eur J Pharmacol. 2000;409:207-211.
65. Adami M, Frati P, Bertini S, et al. Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. Br J Pharmacol. 2002;135:1598-1606.
66. Adami M, Zamfirova R, Sotirov E, et al. Gastric antisecretory effects of synthetic cannabinoids after central or peripheral administration in the rat. Brain Res Bull. 2004;64:357-361.
67. Coruzzi G, Adami M, Guaita E, et al. Effects of cannabinoid receptor agonists on rat gastric acid secretion: discrepancy between in vitro and in vivo data. Dig Dis Sci. 2006;51:310-317.
68. Kimball ES, Schneider CR, Wallace NH, et al. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol. 2006;291:G364-G371.
69. Storr MA, Keenan CM, Zhang H, et al. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis. 2009;15:1678-1685.
70. Storr MA, Keenan CM, Emmerdinger D, et al. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med (Berl). 2008;86:925-936.
71. Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest. 2004;113:1202-1209.
72. Alhamoruni A, Wright KL, Larvin M, et al. Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability. Br J Pharmacol. 2004;165:2598-2610.
73. Cani PD, Plovier H, Hul MV, et al. Endocannabinoids-at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinol. 2015 [Epub ahead of print]; DOI: 10.1038/nrendo.2015.211.
74. Cluny NL, Reimer RA, Sharkey KA. Cannabinoid signalling regulates inflammation and energy balance: the importance of the brain-gut axis. Brain Behav Immun. 2012;26:691-698.
75. Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13:35-37.
76. Muccioli GG, Naslain D, Backhed F, et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol. 2010;6:392.
77. Rietschel ET, Kirikae T, Schade FU, et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J. 1994;8:217-225.
78. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761-1772.
79. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470-1481.